Immix Biopharma, Inc.

Healthcare

NASDAQ:IMMX · NASDAQ Capital Market

Market Cap $496.69M Beta 0.10 P/E (TTM) -10.1

$8.72 +0.99%

+$0.09 today

52W Low $1.94High $11.61

Vol 5.28M · Avg 1.07M

EPS (TTM) -$0.91Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+291.03%

Period High

$11.12

Period Low

$1.96

Latest

$8.72

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

$260.02M

MacroGenics, Inc.

NASDAQ:MGNX

$256.48M

Whitehawk Therapeutics Inc

NASDAQ:WHWK

$209.65M

Surrozen, Inc.

NASDAQ:SRZN

$171.24M

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

$158.59M

Oncolytics Biotech Inc.

NASDAQ:ONCY

$95.99M

Coya Therapeutics, Inc.

NASDAQ:COYA

$88.70M

Pliant Therapeutics, Inc.

NASDAQ:PLRX

$71.21M

Instil Bio, Inc.

NASDAQ:TIL

$51.41M

Atossa Therapeutics, Inc.

ATOS

$16.84M

What is the latest IMMX filing?

The latest filing shown is SC 13G/A dated Jun 5, 2026.

How many recent filings does IMMX have?

Intrinsic Alpha currently shows 20 recent filings for IMMX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.